Summit Therapeutics PLC's (SMMT) stock plummeted 5.04% in the pre-market trading session on Tuesday after the company provided updates on its key clinical trials involving Ivonescimab, its lead investigational candidate targeting PD-1 and VEGF.
During the company's fourth quarter and full-year 2024 earnings call, Summit shared details on the progress of its ongoing global Phase III trials for Ivonescimab. While the company highlighted several milestones achieved, including completing enrollment for the HARMONi trial in advanced non-small cell lung cancer (NSCLC) and initiating the HARMONi-7 trial in first-line metastatic NSCLC patients, the updates failed to impress investors.
One key disappointment was the lack of clarity on the timing for the top-line data readout from the pivotal HARMONi-3 trial, which is evaluating Ivonescimab in combination with chemotherapy as a first-line treatment for metastatic NSCLC. The company stated that it had recently started enrolling non-squamous patients in the U.S. and would initiate site activations in other regions during the second quarter of 2025, but did not provide a concrete timeline for completion of enrollment or data readout.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。